← All trials
NCT01802255
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2013
- Primary completion
- Mar 1, 2020
- Completion date
- Jun 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Fundación Universidad Católica de Valencia San Vicente MártirLead sponsor
- Complejo Asistencial de LeónOverall official - principal investigator
- Universidad de MurciaOverall official - principal investigator
- Basque Country UniversityOverall official - principal investigator
- University of ValenciaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.